| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/31/2006 | WO2006091326A1 Anti-prl-3 antibodies and methods of use thereof |
| 08/31/2006 | WO2006091229A2 Methods of modulating intracellular degradation rates of toxins |
| 08/31/2006 | WO2006091209A2 Bispecific binding agents for modulating biological activity |
| 08/31/2006 | WO2006090968A1 Composition for adjuvant containing poly-gamma-glutamic acid |
| 08/31/2006 | WO2006090932A1 Surrogate marker for sulfonamide compound |
| 08/31/2006 | WO2006090930A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | WO2006090928A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor |
| 08/31/2006 | WO2006090921A1 Inhibitory effect of sulfonamide compound on lymphocyte activation |
| 08/31/2006 | WO2006090900A1 Preventives/remedies for cancer |
| 08/31/2006 | WO2006090853A1 Nitrogenous heterocyclic compound and medicinal use thereof |
| 08/31/2006 | WO2006090816A1 Method of constructing liposome vaccine |
| 08/31/2006 | WO2006090750A1 ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME |
| 08/31/2006 | WO2006090291A2 Method for expanding cd4+ cd25+ t regulatory cells |
| 08/31/2006 | WO2006090096A1 Composition, kit and method for fixing cells |
| 08/31/2006 | WO2006089980A1 Nucleic acids and allergens of olive tree pollen of defined olive tree varieties and applications thereof |
| 08/31/2006 | WO2006089690A1 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| 08/31/2006 | WO2006089549A1 Ykl-40 monoclonal antibodies |
| 08/31/2006 | WO2006074914A3 Human rna helicase and therapeutic uses thereof |
| 08/31/2006 | WO2006073431A3 Avipox recombinants expressing foot and mouth disease virus genes |
| 08/31/2006 | WO2006071206A3 Immunoglobulins whith potent and broad antiviral activity |
| 08/31/2006 | WO2006070286A3 Monoclonal antibodies against nkg2a |
| 08/31/2006 | WO2006065975A3 Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor |
| 08/31/2006 | WO2006064121A3 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations |
| 08/31/2006 | WO2006052660A9 Il-7 receptor blockade to suppress immunity |
| 08/31/2006 | WO2006044908A3 Antibody formulation in histidine-acetate buffer |
| 08/31/2006 | WO2006044566A3 Autocrine growth factor receptors and methods |
| 08/31/2006 | WO2006040481A3 Method for diagnosing and treating crohn's disease |
| 08/31/2006 | WO2006029176A3 Cancer-testis antigens |
| 08/31/2006 | WO2006028956A3 Anti-fc-gamma riib receptor antibody and uses therefor |
| 08/31/2006 | WO2006023403A3 Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| 08/31/2006 | WO2006007529A3 Immunosuppressive exosomes |
| 08/31/2006 | WO2006002064A3 Antibody inhibiting stem cell factor activity and use for treatment of asthma |
| 08/31/2006 | WO2005047307A3 Il-18 binding proteins |
| 08/31/2006 | WO2005038430A3 Viral fibers |
| 08/31/2006 | WO2005016281A3 Diagnosis and treatment of malignant neoplasms |
| 08/31/2006 | WO2005010163A3 Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv) |
| 08/31/2006 | WO2004033648A3 Isolated mammalian membrane protein genes; related reagents |
| 08/31/2006 | US20060194957 Comprising human immunoglobulin g1 fc region; mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 08/31/2006 | US20060194954 Immunoadhesin protein for use as tools in targeting preferential cells for destruction |
| 08/31/2006 | US20060194753 Agent for treating leishmania infections |
| 08/31/2006 | US20060194751 Streptococcus pyogenes antigens |
| 08/31/2006 | US20060194735 Extending the shelf life of Therapeutic protein X; nucleic acids and vectors containing them; kits; treating, preventing, or ameliorating diseases, disorders or conditions |
| 08/31/2006 | US20060194731 Using tumor antigens to elicit immune response targeted to cancer cells; immunotherapy |
| 08/31/2006 | US20060194730 Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| 08/31/2006 | US20060194318 Cultured cd14+ antigen presenting cells |
| 08/31/2006 | US20060194293 Rb1 gene induced protein (rb1cc1) and gene |
| 08/31/2006 | US20060194287 Chemokine-binding protein and methods of use |
| 08/31/2006 | US20060194286 Apo-2LI and Apo-3 polypeptides |
| 08/31/2006 | US20060194265 Novel therapeutic targets in cancer |
| 08/31/2006 | US20060194197 Biosensors utilizing dendrimer-immobilized ligands and their use thereof |
| 08/31/2006 | US20060194196 Novel surface protein (hbsag) variant of the hepatitis B virus |
| 08/31/2006 | US20060193886 Medical devices with nanoporous layers and topcoats |
| 08/31/2006 | US20060193877 Compositions and methods of making sustained release liquid formulations |
| 08/31/2006 | US20060193876 Fusion proteins of Mycobacterium tuberculosis |
| 08/31/2006 | US20060193875 Method of treating human-immunodeficiency virus (hiv) disease infection |
| 08/31/2006 | US20060193874 Vaccines for proliferative ileitis and methods of making and using the same |
| 08/31/2006 | US20060193873 Functionallly reconstituted viral membranes containing adjuvant |
| 08/31/2006 | US20060193872 Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers |
| 08/31/2006 | US20060193871 transmission and, or amplification of signal; oral or enteric administering, dissolving, absorption; peptide yy; obesity therapy |
| 08/31/2006 | US20060193870 Compositions and methods for the therapy and diagnosis of colon cancer |
| 08/31/2006 | US20060193869 Methods and compositions for induction or promotion of immune tolerance |
| 08/31/2006 | US20060193868 graphitic nanotubes substituted with chemical moieties or upon which certain cyclic compounds are adsorbed; complex structures comprised of such functionalized fibrils linked to one another; introducing functional groups onto the surface of such fibrils |
| 08/31/2006 | US20060193867 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
| 08/31/2006 | US20060193866 H pylori antigens |
| 08/31/2006 | US20060193865 Camptothecin-binding moiety conjugates |
| 08/31/2006 | US20060193864 Conversion of apoptotic proteins |
| 08/31/2006 | US20060193863 Compositions and methods for diagnosing and treating prostate cancer |
| 08/31/2006 | US20060193862 Vascular endothelial cell growth factor antagonists |
| 08/31/2006 | US20060193861 Tumor necrosis factor receptors 6 alpha & 6 beta |
| 08/31/2006 | US20060193860 Treatment of schizophrenia |
| 08/31/2006 | US20060193859 Methods of Treatment Using Antibodies to Neutrokine-alpha |
| 08/31/2006 | US20060193858 Full-lenth, isolated polypeptide comprising a polypeptide sequence of human SRC-like adaptor protein |
| 08/31/2006 | US20060193857 Modulation of Fc gamma receptors for optimizing immunotherapy |
| 08/31/2006 | US20060193856 Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
| 08/31/2006 | US20060193855 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 08/31/2006 | US20060193854 a cancer which expresses epidermal growth factor receptor; blocking ligand activation of a receptor; binding of monoclonal antibody 2C4 to ErbB2; chemotherapeutic agents are 5-fluorouracil leucovorin, levamisole |
| 08/31/2006 | US20060193853 Combinations of growth-and hormone-regulating factors for the treatment of neoplasia |
| 08/31/2006 | US20060193852 immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma; single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen; domains are arranged in the order VLCD19-VHCD19-VHCD3-VLCD3; vector; cell |
| 08/31/2006 | US20060193851 Human anti-factor IX/IXa antibodies |
| 08/31/2006 | US20060193850 Anti a beta antibody formulation |
| 08/31/2006 | US20060193849 Biological materials and uses thereof |
| 08/31/2006 | US20060193848 Mammalian tumor susceptibility genes and their uses |
| 08/31/2006 | US20060193847 Peptides for inhibiting retroviruses |
| 08/31/2006 | US20060193834 Antiprotozal composition |
| 08/31/2006 | US20060193828 Expression enhancer for HM1.24 antigen |
| 08/31/2006 | US20060193820 Immunostimulating polyphosphazene compounds |
| 08/31/2006 | US20060193778 Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| 08/31/2006 | US20060193772 Drugs for treating cancer |
| 08/31/2006 | US20060193771 Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| 08/31/2006 | CA2599606A1 Bispecific binding agents for modulating biological activity |
| 08/31/2006 | CA2599439A1 Ykl-40 monoclonal antibody |
| 08/31/2006 | CA2599301A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor |
| 08/31/2006 | CA2599115A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | CA2598684A1 Porcine helicobacter infection |
| 08/31/2006 | CA2598666A1 Intranasal administration of active agents to the central nervous system |
| 08/31/2006 | CA2598004A1 Adamts-7 as a biomarker for cancers of epithelial origin |
| 08/31/2006 | CA2596133A1 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
| 08/31/2006 | CA2593532A1 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| 08/31/2006 | CA2571982A1 Methods of modulating intracellular degradation rates of toxins |
| 08/30/2006 | EP1696033A2 Pseudomonas exotoxin A-like chimeric immunogens |